Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform. Our alphalex™ platform allows small molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment and tumor cells, directly delivering drugs to tumors. It enables antigen-independent targeting of tumors and metastases with deep tissue penetration for small molecule anti-cancer drugs. The enhanced therapeutic index allows combinations of therapies with known synergistic efficacy at doses which were previously thought to be unreachable due to synergistic toxicity. Cybrexa is able to:
– Rapidly bring novel compounds with robust IP to pivotal studies
– Enable highly potent drugs and combination therapies that are currently limited by toxicity
– Expand efficacy of existing anticancer agents to larger, high unmet need populations
The company anticipates its lead program, CBX-12 (alphalex™-exatecan), will enter Phase I/II in early 2021. CBX-12 is an alphalex™ conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its strong efficacy and solid safety profile demonstrated to date in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs. Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021, with clinical efficacy and safety data expected by 2022.
Sep 13, 2019
Posted by Cybrexa Therapeutics